Carpomya vesuviana A. Costa (Diptera Tephritidae Trypetinae Carpomyini) from jujube tree in Emilia-Romagna (Northern Italy)

The presence of Carpomya vesuviana (Diptera Tephritidae) on fruit of jujube tree (Ziziphus jujuba) in Emilia- Romagna (Northern Italy) is reported. Some aspects of the biology of the species are described. Differently from southern regions, where C. vesuviana is polivoltine, in Emilia-Romagna only one generation per year occurs.

Sirolimus for calcineurin inhibitors in organ transplantation: contra

n/

Ants (Hymenoptera Formicidae) and the food industry: observations in factory premises in central Italy

Research on ants (Hymenoptera Formicidae) in a food factory in the province of Latina (Lazio, central Italy) was carried out over several years up to 2013. The investigation started during the 1990s, and was conducted principally by examining specimens caught in light traps placed indoors on the factory premises. A smaller number of ants was collected directly during periodical inspections. The present work focuses on the observations made on specimens collected during 2007 and 2008 using light traps. Besides some ant genera and species which are well known as being typical pests of the food industry, some other more unusual and sporadic species were found. Among these latter, females of the ponerine ant Hypoponera punctatissima were sometimes collected in dozens or hundreds during single weeks of sampling using light traps. Many specimens of Pheidole pallidula (males, females, workers and soldiers) and Lasius spp. (males) were also collected using traps. H. eduardi, Cremastogaster scutellaris, Solenopsis fugax and Linepithema humile were scarce or extremely scarce in the traps, as were species of Myrmica, Aphaenogaster, Messor, Tetramorium, and Camponotus. The causes of their presence in the food factory may differ according to genera and species, and deserve to be studied in depth

Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation

Dual induction with low doses of rabbit anti-human thymoglobulin (RATG) and basiliximab effectively and safely prevented allograft rejection in high-risk renal transplant recipients. To assess whether treatment timing affects efficacy and tolerability, in this single-center, matched-cohort study, we compared posttransplant outcomes in 25 patients and 50 gender-, age-, and treatment-matched reference patients induced with the same course of 7 daily RATG infusions (0.5 mg/kg/day) started before or after engraftment, respectively. All subjects received basiliximab (20 mg) before and 4 days after transplantation, withdrew steroids within 6 days after surgery, and were maintained on steroid-free immunosuppression with cyclosporine and mycophenolate mofetil or azathioprine. Over 12 months after transplant, 1 patient (4%) and 13 reference patients (26%) had acute rejection episodes. One patient and 5 reference-patients required dialysis therapy because of delayed graft function. In all patients circulating CD4+ and CD8+ T lymphocytes were fully depleted before engraftment. Both treatments were well tolerated. In kidney transplantation, perioperative RATG infusion enhances the protective effect of low-dose RATG and basiliximab induction against graft rejection and delayed function, possibly because of more effective inhibition of early interactions between circulating T cells and graft antigens

Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4–60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18–6.42), P = .0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy

Long-Term Outcome of Renal Transplantation from Older Donors

n/

Clinical Study Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial

Background. The effect of angiotensin converting enzyme inhibitors (ACEi) on regression of retinopathy in type 2 diabetics is still ill defined. Methods. We compared the incidence of retinopathy regression in 90 hypertensive type 2 diabetics randomized to at least 3-year blinded ACEi with trandolapril (2 mg/day) or non-ACEi therapy who had preproliferative or proliferative retinopathy at baseline. Results. Over a median (interquartile range) follow-up period of 35.8 (12.4-60.7) months, retinopathy regressed in 27 patients (30.0%). Regression occurred in 18 of 42 patients (42.9%) on ACEi and in 9 of 48 (18.8%) on non-ACEi therapy (adjusted for predefined baseline covariates HR (95% CI): 2.75 (1.18-6.42), P = .0193). Concomitant treatment with or without Non-Dihydropyridine Calcium Channel Blockers (ndCCBs) did not appreciably affect the incidence of retinopathy regression. Conclusions. Unlike ndCCB, ACEi therapy may have an additional effect to that of intensified BP and metabolic control in promoting regression of diabetic retinopathy